Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer

Journal of the National Cancer Institute

Volumn 105, Issue 21, 2013, Pages 1617-1627

  Liu, Dingxie ^a   Yang, Chongfei ^a   Bojdani, Ermal ^a   Murugan, Avaniyapuram Kannan ^a   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

AMINO ACID SEQUENCE; ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CONTROLLED STUDY; DEMETHYLATION; EXON; FEMALE; GENE IDENTIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHYLATION; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASAL1 GENE; STABLE EXPRESSION; THYROID CANCER; TRANSIENT EXPRESSION; TUMOR SUPPRESSOR GENE; WILD TYPE;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; CELL LINE, TUMOR; DNA METHYLATION; GENES, TUMOR SUPPRESSOR; GTPASE-ACTIVATING PROTEINS; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; RAS GTPASE-ACTIVATING PROTEINS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84890466783     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt249     Document Type: Article

References (40)

1. Rebollo A, Martinez A. Ras proteins: recent advances and new functions. Blood. 1999;94(9):2971-2980.
2. Vigil D, Cherfils J, Rossman KL, et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10(12):842-857.
3. Kolfschoten IG, van Leeuwen B, Berns K, et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 2005;121(6):849-858.
4. Jin H, Wang X, Ying J, et al. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-Activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci U S A. 2007;104(30):12353-12358.
5. Ohta M, Seto M, Ijichi H, et al. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology. 2009;136(1):206-216.
6. Yohay KH. The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol. 2006;13(1):21-26.
7. Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005;102(24):8573-8578.
8. Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol. 2002;17(8):562-570.
9. Wakioka T, Sasaki A, Kato R, et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature. 2001;412(6847):647-651.
10. Sasaki A, Taketomi T, Wakioka T, et al. Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factorbut not epidermal growth factor-induced ERK activation. J Biol Chem. 2001;276(39):36804-36808.
11. Granovsky AE, Rosner MR. Raf kinase inhibitory protein: A signal transduction modulator and metastasis suppressor. Cell Res. 2008;18(4):452-457.
12. Ueda K, Arakawa H, Nakamura Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene. 2003;22(36):5586-5591.
13. Furukawa T, Sunamura M, Motoi F, et al. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 2003;162(6):1807-1815.
14. Wrighton KH. Tumour suppressors: Role of nuclear PTEN revealed. Nat Rev Cancer. 2011;11(3):154.
15. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene. 2008;27(55):6908-6919.
16. van Veelen W, Korsse SE, van de LL, et al. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene. 2011;30(20):2289-2303
17. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114-128.
18. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med. 2006;12(3):283-285.
19. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39(9):1120-1126.
20. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/csr/1975-2009- pops09. Accessed August 13, 2013.
21. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
22. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998;83(12):2638-2648.
23. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184-199.
24. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-262.
25. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742-762.
26. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697-706.
27. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161-1170.
28. Liu D, Hou P, Liu Z, et al. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res. 2009;69(18):7311-7319.
29. Liu D, Hu S, Hou P, et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007;13(4):1341-1349.
30. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440-2447.
31. Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004;64(5):1664-1668.
32. Ishizaka Y, Ushijima T, Sugimura T, et al. cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun. 1990;168(2):402-408.
33. Shapira S, Barkan B, Friedman E, et al. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Rasindependent pathways. Cell Death Differ. 2007;14(5):895-906.
34. Nur-E-Kamal MS, Varga M, Maruta H. The GTPase-Activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype. J Biol Chem. 1993;268(30):22331-22337.
35. Gutmann DH, Collins FS. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron. 1993;10(3):335-343.
36. Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010;107(23):10649-10654.
37. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12):4700-4711.
38. Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006;119(10):2322-2329.
39. Scheffzek K, Lautwein A, Kabsch W, et al. Crystal structure of the GTPaseactivating domain of human p120GAP and implications for the interaction with Ras. Nature. 1996;384(6609):591-596.
40. Todorova A, Danieli GA. Large majority of single-nucleotide mutations along the dystrophin gene can be explained by more than one mechanism of mutagenesis. Hum Mutat. 1997;9(6):537-547.